During neuropathological states associated with inflammation, the levels of cytokines such as interleukin-1 (IL-1) are increased. Several studies have suggested that the neuronal damage observed in pathogenesis implicating IL-1 are caused by an alteration in the neurochemical interactions between neurons and astrocytes. We report here that treating striatal astrocytes in primary culture with IL-1 for 22-24 hr enhances the ATP-evoked release of arachidonic acid (AA) with no effect on the ATP-induced accumulation of inositol phosphates. The molecular mechanism responsible for this effect involves the expression of P 2Y2 receptors (a subtype of purinoceptor activated by ATP) and cytosolic phospholipase A2 (cPLA 2 , an enzyme that mediates AA release). Indeed, P 2Y2 antisense oligonucleotides reduce the ATP-evoked release of AA only from IL-1-treated astrocytes. Further, both the amount of cPLA2 (as assessed by Western blotting) and the release of AA resulting from direct activation of cPLA 2 increased fourfold in cells treated with IL-1. We also report evidence indicating that the coupling of newly expressed P 2Y2 receptors to cPLA 2 is dependent on PKC activity. These results suggest that during inflammatory conditions, IL-1 reveals a functional P 2Y2 signaling pathway in astrocytes that results in a dramatic increase in the levels of free AA. This pathway may thus contribute to the neuronal loss associated with cerebral ischemia or traumatic brain injury.Key words: purinoceptor; phospholipase; cytokine; inflammation; glutamate; neurotoxicity ATP acts both as an intracellular source of energy and an intercellular signaling molecule. Several studies carried out in smooth muscle nerve endings, peripheral ganglia, and brain have shown that ATP is (1) stored in neuronal vesicles; (2) released in a Ca 2ϩ -dependent manner; (3) able to activate specific receptors; and (4) hydrolyzed by ecto-ATPases (for review, see Zimmermann, 1994). By way of illustration, it is present in synaptic vesicles of cholinergic interneurones of the striatum where it is co-localized and co-released with acetylcholine (Richardson and Brown, 1987).This purine binds to and activates a family of purinoceptors (P 2 receptors) namely P 2X , P 2Y , P 2U , P 2Z , and P 2T , which have been classified based on the potencies of structural ATP analogs (Fredholm et al., 1994). For most of them, cDNAs have been cloned and characterized (Lustig et al